Skip to main content
. Author manuscript; available in PMC: 2023 Feb 17.
Published in final edited form as: Semin Arthritis Rheum. 2022 Oct 17;57:152106. doi: 10.1016/j.semarthrit.2022.152106

Table 3.

Comparison of SLE cases prescribed vs. not prescribed PJP prophylaxis.

SLE Cases (n = 977) Prescribed PJP
Prophylaxis(n =
170)* 		Not Prescribed PJP
Prophylaxis(n =
841)		 p
value
Current age**, mean ± SD 43.5 ± 14.4 56.8 ± 16.4 <0.001
Age at first SLE billing code, years, mean ± SD 28.6 ± 13.5 40.7 ± 16.0 <0.001
Sex, n (%)
Female 144/168 (86) 767/840 (91) 0.02
Male 24/168 (14) 73/840 (9)
Race
White 73/167 (44) 561/792 (71) <0.001
Black 82/167 (49) 186/792 (23)
Asian 7/167 (4) 17/792 (2)
Other 5/167 (3) 28/792 (4)
Ethnicity
 Hispanic 7/165 (4) 28/794 (4) 0.66
SLE nephritis ***
 Present 119/170 (70) 154/839 (18) <0.001
Renal Transplant recipient
 Present 64/170 (38) 13/841 (2) <0.001
*

N refers to occurrence of PJP prophylaxis with 170 occurrences of PJP prophylaxis to 132 unique SLE cases.

**

Current age refers to age at time of analysis.

***

SLE nephritis defined by renal biopsy or clinical diagnosis by rheumatologist or nephrologist.